Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized IMMU-LL2: Treatment With 90Y-hLL2 IgG

NCT00421395 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00421395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00421395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized IMMU-LL2: Treatment With 90Y-hLL2 IgG
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2002
Completion date
October 31, 2007
Enrollment
59 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell nhl, nhl, non-hodgkins lymphoma